[HTML][HTML] Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a …
WT Garvey, DH Ryan, M Look, KM Gadde… - The American journal of …, 2012 - Elsevier
Background: Obesity is a serious chronic disease. Controlled-release phentermine/
topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown
significant weight loss compared with placebo in a 56-wk study in overweight and obese
subjects with≥ 2 weight-related comorbidities. Objective: This study evaluated the long-term
efficacy and safety of PHEN/TPM CR in overweight and obese subjects with cardiometabolic
disease. Design: This was a placebo-controlled, double-blind, 52-wk extension study; …
topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown
significant weight loss compared with placebo in a 56-wk study in overweight and obese
subjects with≥ 2 weight-related comorbidities. Objective: This study evaluated the long-term
efficacy and safety of PHEN/TPM CR in overweight and obese subjects with cardiometabolic
disease. Design: This was a placebo-controlled, double-blind, 52-wk extension study; …